Overview

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Key objectives of this clinical study are to: - Determine how well intramuscular (IM) olanzapine depot works compared to placebo - Evaluate the safety and tolerability of IM olanzapine depot compared to placebo - Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine